Global Biologics Safety Testing Market Size By Type (Endotoxin Tests, Sterility Tests), By Application (Vaccine Development, Blood s Testing), By Region, And Segment Forecasts, 2023 to 2032

lobal Biologics Safety Testing Market Report Description

The Global Biologics Safety Testing Market was valued at USD 5.6 billion in 2023 and is projected to surpass USD 10.4 billion by 2031, growing at a CAGR of 8.1% during the forecast period of 2023–2031.

The market’s growth is primarily driven by the rising demand for biologics, including monoclonal antibodies, vaccines, and cell & gene therapies. Biologics safety testing plays a crucial role in ensuring product quality, efficacy, and patient safety by detecting contaminants like endotoxins, mycoplasma, and viral particles. With the expansion of the biopharmaceutical sector and stricter regulatory guidelines, the demand for advanced safety testing solutions is witnessing rapid growth.

Furthermore, the increasing investments in biopharmaceutical research, growing outsourcing of testing services, and the adoption of rapid microbiological methods are accelerating market expansion globally.

Drivers

Rising Production of Biologics

The increasing development and commercialization of biologics for chronic diseases such as cancer, autoimmune disorders, and infectious diseases are driving the need for extensive safety testing to comply with regulatory standards.

Stringent Regulatory Guidelines

Agencies like the FDA, EMA, and WHO mandate rigorous biologics safety testing before product approval. Compliance with these stringent regulations fuels the adoption of advanced testing kits, reagents, and services.

Technological Advancements

The introduction of automated and high-throughput testing platforms, rapid endotoxin detection assays, and next-generation sequencing for viral safety testing is enhancing the reliability and efficiency of safety testing procedures.

Restraints

High Testing Costs

The cost of biologics safety testing, especially viral safety and sterility testing, can be prohibitive for small-scale manufacturers, thereby impacting market penetration in cost-sensitive regions.

Complexity of Biologics

Biologics are inherently complex molecules, making their safety testing more challenging compared to small-molecule drugs. This complexity increases turnaround times and operational expenses.

Opportunities

Growing Outsourcing of Testing Services

Biopharmaceutical companies are increasingly outsourcing biologics safety testing to contract research organizations (CROs) to save time and reduce infrastructure costs, creating lucrative opportunities for testing service providers.

Rising Demand in Emerging Markets

Rapidly developing healthcare infrastructure and growing biopharmaceutical manufacturing in Asia-Pacific and Latin America are opening new growth avenues for biologics safety testing solutions.

Adoption of Rapid Testing Methods

The shift towards real-time, rapid microbiological methods (RMM) offers opportunities to improve efficiency and reduce product release timelines, driving further adoption.

Market by System Type Insights

Based on system type, the Endotoxin Testing segment dominated the market in 2023, driven by the need for endotoxin-free biologics to ensure patient safety. However, the Viral Safety Testing segment is expected to grow at the highest CAGR during the forecast period, fueled by the rise in viral vector-based gene therapies and vaccines.

Market by End-use Insights

Based on end-use, the Biopharmaceutical Companies segment accounted for the largest market share in 2023. The increasing production of complex biologics and biosimilars has amplified the need for robust safety testing. Meanwhile, the Contract Research Organizations (CROs) segment is expected to witness significant growth as more companies outsource testing activities to reduce operational burdens.

Market by Regional Insights

North America held the largest market share in 2023, supported by a strong biopharmaceutical industry, advanced testing technologies, and strict regulatory guidelines.

Europe remains a key market, driven by increasing biologics production and the presence of leading pharmaceutical companies.

Asia-Pacific is projected to grow at the fastest rate, fueled by expanding biomanufacturing facilities in China, India, and South Korea, along with supportive government initiatives.

Competitive Scenario

Key players in the Global Biologics Safety Testing Market include Charles River Laboratories, Lonza Group, Merck KGaA, Thermo Fisher Scientific, WuXi AppTec, Eurofins Scientific, Sartorius AG, SGS SA, Bio-Rad Laboratories, and Nelson Labs.

These companies are focusing on:

Strategic acquisitions to expand service offerings

Launching advanced testing kits and platforms

Partnerships with biopharma companies to strengthen their global presence

Recent Developments:

April 2024: Lonza launched a new rapid sterility testing platform to reduce product release timelines for biologics.

January 2024: Charles River Laboratories expanded its viral safety testing capabilities through the acquisition of a leading CRO in Europe.

September 2023: Merck introduced an advanced mycoplasma detection kit leveraging PCR technology for faster turnaround times.

Scope of Work – Global Biologics Safety Testing Market

Key Market Developments

Lonza launched a next-gen endotoxin detection assay in 2024 to enhance biologics safety testing efficiency.

WuXi AppTec expanded its biologics safety testing labs in Asia-Pacific in 2023 to cater to the growing demand from regional biomanufacturers.

Thermo Fisher Scientific partnered with a leading gene therapy company in 2023 to provide viral clearance testing solutions.

FAQs

What is the current market size of the Global Biologics Safety Testing Market?

The market was valued at USD 5.6 billion in 2023.

What is the major growth driver of the Global Biologics Safety Testing Market?

The rising production of biologics and stringent regulatory guidelines are the key growth drivers.

Which is the largest region during the forecast period in the Global Biologics Safety Testing Market?

North America remains the largest region due to its advanced biopharma sector and strict compliance requirements.

Which segment accounted for the largest market share in the Global Biologics Safety Testing Market?

Endotoxin Testing accounted for the largest share in 2023, driven by the need for endotoxin-free biologics.

Who are the key market players in the Global Biologics Safety Testing Market?

Key players include Charles River, Lonza Group, Merck KGaA, Thermo Fisher Scientific, WuXi AppTec, and Eurofins Scientific.

Would you like me to create similar structured reports for the remaining markets you uploaded, or should I generate a comparison chart of key metrics for all markets together?